DDInter1326 DDInter915
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Olanzapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Ipratropium {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiotropium
Tiotropium {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Ipratropium {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Ipratropium {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Olanzapine {u} (Compound) binds {v} (Gene) HRH4
HRH4 {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium and Tiotropium (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Olanzapine (Compound) binds HRH4 (Gene) and HRH4 (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)